AIMS: We investigated whether myeloid-related protein 8/14 complex (MRP8/14) expressed by infiltrating monocytes and granulocytes may represent a mediator and early biomarker of acute coronary syndromes (ACS). METHODS AND RESULTS: Immunohistochemistry of coronary thrombi was done in 41 ACS patients. Subsequently, levels of MRP8/14 were assessed systemically in 75 patients with ACS and culprit lesions, with stable coronary artery disease (CAD), or with normal coronary arteries. In a subset of patients, MRP8/14 was measured systemically and at the site of coronary occlusion. Macrophages and granulocytes, but not platelets stained positive for MRP8/14 in 76% of 41 thrombi patients. In ACS, local MRP8/14 levels [22.0 (16.2-41.5) mg/L] were increased when compared with systemic levels [13.4 (8.1-14.7) mg/L, P = 0.03]. Systemic levels of MRP8/14 were markedly elevated [15.1 (12.1-21.8) mg/L, P = 0.001] in ACS when compared with stable CAD [4.6 (3.5-7.1) mg/L] or normals [4.8 (4.0-6.3) mg/L]. Using a cut-off level of 8 mg/L, MRP8/14 but not myoglobin or troponin, identified ACS presenting within 3 h from symptom onset. CONCLUSION: In ACS, MRP8/14 is markedly expressed at the site of coronary occlusion by invading phagocytes. The occurrence of elevated MRP8/14 in the systemic circulation prior to markers of myocardial necrosis makes it a prime candidate for the detection of unstable plaques and management of ACS.
AIMS: We investigated whether myeloid-related protein 8/14 complex (MRP8/14) expressed by infiltrating monocytes and granulocytes may represent a mediator and early biomarker of acute coronary syndromes (ACS). METHODS AND RESULTS: Immunohistochemistry of coronary thrombi was done in 41 ACS patients. Subsequently, levels of MRP8/14 were assessed systemically in 75 patients with ACS and culprit lesions, with stable coronary artery disease (CAD), or with normal coronary arteries. In a subset of patients, MRP8/14 was measured systemically and at the site of coronary occlusion. Macrophages and granulocytes, but not platelets stained positive for MRP8/14 in 76% of 41 thrombipatients. In ACS, local MRP8/14 levels [22.0 (16.2-41.5) mg/L] were increased when compared with systemic levels [13.4 (8.1-14.7) mg/L, P = 0.03]. Systemic levels of MRP8/14 were markedly elevated [15.1 (12.1-21.8) mg/L, P = 0.001] in ACS when compared with stable CAD [4.6 (3.5-7.1) mg/L] or normals [4.8 (4.0-6.3) mg/L]. Using a cut-off level of 8 mg/L, MRP8/14 but not myoglobin or troponin, identified ACS presenting within 3 h from symptom onset. CONCLUSION: In ACS, MRP8/14 is markedly expressed at the site of coronary occlusion by invading phagocytes. The occurrence of elevated MRP8/14 in the systemic circulation prior to markers of myocardial necrosis makes it a prime candidate for the detection of unstable plaques and management of ACS.
Authors: Daria N Kashirina; Andrew J Percy; Liudmila Kh Pastushkova; Christoph H Borchers; Kirill S Kireev; Vladimir A Ivanisenko; Alexey S Kononikhin; Eugene N Nikolaev; Irina M Larina Journal: BMC Med Genomics Date: 2019-03-13 Impact factor: 3.063
Authors: Amit N Vora; Marc P Bonaca; Christian T Ruff; Petr Jarolim; Sabina Murphy; Kevin Croce; Marc S Sabatine; Daniel I Simon; David A Morrow Journal: J Thromb Thrombolysis Date: 2012-08 Impact factor: 2.300
Authors: Kristin Angel; Sella A Provan; Magne K Fagerhol; Petter Mowinckel; Tore K Kvien; Dan Atar Journal: Am J Hypertens Date: 2012-03-01 Impact factor: 2.689
Authors: Michał Wiciński; Bartosz Malinowski; Mateusz M Węclewicz; Elżbieta Grześk; Grzegorz Grześk Journal: Exp Ther Med Date: 2017-03-02 Impact factor: 2.447
Authors: Ling Yan; Per Bjork; Radu Butuc; Joseph Gawdzik; Judy Earley; Gene Kim; Marion A Hofmann Bowman Journal: Atherosclerosis Date: 2013-02-28 Impact factor: 5.162
Authors: Kevin Croce; Huiyun Gao; Yunmei Wang; Toshifumi Mooroka; Masashi Sakuma; Can Shi; Galina K Sukhova; René R S Packard; Nancy Hogg; Peter Libby; Daniel I Simon Journal: Circulation Date: 2009-07-20 Impact factor: 29.690
Authors: Klaus Burkhardt; Sonja Schwarz; Chengrui Pan; Felix Stelter; Konstantin Kotliar; Maxilian Von Eynatten; Daniel Sollinger; Ines Lanzl; Uwe Heemann; Marcus Baumann Journal: Cardiovasc Diabetol Date: 2009-02-20 Impact factor: 9.951